Whole-of-population CRISPR point-of-care testing for congenital cytomegalovirus to prevent hearing and neurodevelopment disabilities through a public health approach

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2006491

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Congenital cytomegalovirus infection (cCMV) is the major infective cause of deafness and brain disability, both of which are potentially reversible with early treatment. Currently, there is no screening at birth, and cCMV is diagnosed too late for treatment. Our team will test and validate CRISPR, a new and cheap technology, on 110,000+ newborns to detect cCMV. This will revolutionise how cCMV is detected, make treatment more accessible and pave way to lower rates of deafness and cerebral palsy.

Funded Activity Details

Start Date: 01-01-2021

End Date: End date not available

Funding Scheme: Clinical Trials and Cohort Studies Grants

Funding Amount: $2,058,920.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cytomegalovirus (cmv) infection | population screening | public health costs | treatment

Related Links